This message contains images. If you don't see images, click here to view.
Advertise in this news brief.

Text Version    RSS    Subscribe    Unsubscribe    Archive    Media Kit           September 10, 2014

Home     About SGO    Education    Membership    Clinical Practice    Public Policy    Blog    Partnerships    Store


Researcher urges wider genetic screening for breast cancer
A prominent scientist has started a big new debate about breast cancer. Geneticist Mary-Claire King of the University of Washington, who identified the first breast cancer gene, is recommending that all women get tested for genetic mutations that can cause breast cancer. "My colleagues and I are taking a really bold step," King said. "We're recommending that all adult women in America, regardless of their personal history and regardless of their family history, be offered genetic testing for the breast cancer genes."
   Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article


PNAS study: Screen all Ashkenazi-Jewish women for BRCA mutations
The Jerusalem Post
Instead of Ashkenazi women being tested for the two defective BRCA genes only if a close blood relative contracted breast or ovarian cancer, an Israeli research team that also included Mary-Claire King, PhD, of University of Washington recommends that all women of Ashkenazi origin be screened for the genetic mutations from age 30. This important finding, which could lead later to screening recommendations in non-Jewish populations, was published in the prestigious PNAS journal and aroused interest around the world.
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article

Myriad publishes myRisk hereditary cancer study in cancer
Myriad Genetics, Inc., announced that the Myriad myRisk™ Hereditary Cancer test significantly improved the detection of cancer-causing mutations by 46 percent in patients with breast cancer in a new study published in the journal Cancer. In this study, researchers at Beth Israel Deaconess Medical Center, Dana Farber Cancer Institute and Massachusetts General Hospital Cancer Center used the myRisk test to determine the frequency of hereditary cancer mutations in 2,158 individuals with a history of breast cancer, including 1,781 referred for commercial BRCA1/2 testing, and 377 patients with a personal and family history who previously tested negative for BRCA mutations.
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article

  ChemoFx Improves Ovarian Cancer Outcomes
ChemoFx® provides invaluable information to physicians choosing from 20+ equivalent treatment recommendations without prior knowledge of how individual patients may respond. ChemoFx determines platinum resistance in primary ovarian cancer and demonstrates longer overall survival by 14 months in recurrent ovarian cancer, making it instrumental in improving patient outcomes.


FDA OKs Merck drug, 1st in new cancer drug class
The Washington Post
Merck & Co. won the first U.S. approval for a new kind of cancer drug with big advantages over chemotherapy and other older cancer treatments. The Food and Drug Administration said it has granted accelerated approval to Merck’s Keytruda, for treating melanoma that’s spread or can’t be surgically removed, in patients previously treated with another cancer drug.
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article

Work for the best
We are seeking a gyn-oncologist to join our growing health system in Springfield, Mo. Our clinic has on-site lab and radiology services, access to a da Vinci® surgical robot and a strong support staff. For more information about this opportunity at our physician owned and operated clinic, call 1-800-869-4201. MORE
Exceptional Care, Close to Home

21st Century Oncology – the nation’s largest cancer treatment network and global leader in cancer care – providing integrated clinical teams treating patients collaboratively to improve outcomes.


Combination ovarian cancer therapy granted fast track status
VentiRx announced that the FDA has granted Fast Track designation to motolimod (VTX-2337) when administered in combination with pegylated liposomal doxorubicin (PLD) for the treatment of women with ovarian cancer whose disease has progressed on or recurred after platinum-based chemotherapy. Motolimod is a toll-like receptor 8 (TLR8) agonist that directly activates human myeloid dendritic cells (mDCs), monocytes, and natural killer (NK) cells.
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article

WNT7A/β-catenin signaling induces FGF1 and influences sensitivity to niclosamide in ovarian cancer
Authors of a study published Sept. 1 in Oncogene had previously characterized the link between WNT7A and the progression of ovarian cancer. Other groups have identified FGF1 as a relevant risk factor in ovarian cancer. The latest study shows a linkage between these two signaling pathways that may be exploited to improve treatment and prognosis of patients with ovarian cancer.
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article


Double mastectomies don't yield expected results, study finds
More women are choosing to have bilateral mastectomies when they are diagnosed with early-stage breast cancer, even though there's little evidence that removing both breasts improves their survival compared with more conservative treatments. The biggest study yet on the question has found no survival benefit with bilateral mastectomy compared with breast-conserving surgery with radiation. The study, published in JAMA, the journal of the American Medical Association, looked at the records of all women in California who were diagnosed with early-stage breast cancer from 1998 to 2011 — 189,734 women, all told.
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article

ASCO updates guidelines for HER2-negative breast cancer
Cancer Network
The American Society of Clinical Oncology (ASCO) has updated its clinical practice guideline on both targeted therapies and chemotherapy treatment for women with HER2-negative breast cancer, which makes up approximately 80 percent of all breast cancers diagnosed in the United States. According to the guideline, hormonal therapy, rather than chemotherapy, is the preferred first-line therapy for patients with estrogen receptor–positive metastatic breast cancer, except in cases of immediate life-threatening disease or when a patient is suspected to be resistant to hormonal
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article

Women's Cancer News
Colby Horton, Vice President of Publishing, 469.420.2601
Download media kit

Jessica Taylor, Senior Medical Editor, 202-684-7169  
Contribute news

Inclusion of advertisements does not constitute SGO endorsement of company products or services.

Be sure to add us to your address book or safe sender list so our emails get to your inbox. Learn how.

This edition of the Women's Cancer News was sent to ##Email##. To unsubscribe, click here. Did someone forward this edition to you? Subscribe here — it's free!

Recent issues

Sept. 3, 2014
Aug. 27, 2014
Aug. 20, 2014
Aug. 6, 2014

7701 Las Colinas Ridge, Ste. 800, Irving, TX 75063